SHIFT AI Newsroom · GLOBAL
Research suggests higher dose of semaglutide may lower incidence of neuropsychiatric events
A study found that a higher dose of semaglutide is associated with a lower incidence of neuropsychiatric events, independent of weight loss
Research published on Europe PMC found that a higher dose of semaglutide is associated with a lower incidence of neuropsychiatric events, independent of weight loss. The study's findings may be relevant to UK patients taking semaglutide, but further review is needed to fully understand the implications.
What this means in the UK
This research may be relevant to UK patients taking semaglutide, as it suggests a potential benefit of higher dosages on mental health outcomes
Known facts
- Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss